NCT02893332: Sindas

Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas)

Terminated Phase 3 Last updated 3 February 2021

What this trial tests

Phase 3 trial testing Radiation: SBRT in Stage IV EGFR Mutated Non-Small Cell Lung Cancer in 200 participants. Terminated before completion.

Timeline

15 January 2016

Primary endpoint
30 August 2020

30 August 2020

Quick facts

Lead sponsor	Sichuan Provincial People's Hospital
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	200
Start date	15 January 2016
Primary completion	30 August 2020
Estimated completion	30 August 2020
Sites	1 location across China

Drugs / interventions tested

• Radiation: SBRT
• TKI (Gefitinib or Tarceva ) — full drug profile →

Conditions studied

• Stage IV EGFR Mutated Non-Small Cell Lung Cancer — all drugs for Stage IV EGFR Mutated Non-Small Cell Lung Cancer →

Sponsor

Sichuan Provincial People's Hospital

Who can join

Adults 18 to 99, any sex, with Stage IV EGFR Mutated Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To tested if the adding of consolidative SBRT to TKI in EGFR mutated patients with less than or equal to 5 metastatic sites (primary + 5) will improve progression free survival (PFS) compared to TKI alone.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer.
   Wang XS, Bai YF, Verma V, Yu RL, et al · · 2023 · cited 202× · PMID 35094066 · DOI 10.1093/jnci/djac015
2. Future cancer research priorities in the USA: a Lancet Oncology Commission.
   Jaffee EM, Dang CV, Agus DB, Alexander BM, et al · · 2017 · cited 144× · PMID 29208398 · DOI 10.1016/s1470-2045(17)30698-8
3. Metastasis-directed therapy for oligometastasis and beyond.
   Beckham TH, Yang TJ, Gomez D, Tsai CJ. · · 2021 · cited 36× · PMID 33204024 · DOI 10.1038/s41416-020-01128-5
4. Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management.
   Borgeaud M, Olivier T, Bar J, Saw SPL, et al · · 2025 · cited 16× · PMID 40673977 · DOI 10.3322/caac.70024
5. Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study.
   Wei H, Zhou X, Yang H, Gong Y, et al · · 2022 · cited 15× · PMID 34669037 · DOI 10.1007/s00432-021-03831-z
6. Local ablative therapies in oligometastatic NSCLC-upfront or outback?-a narrative review.
   Tjong MC, Louie AV, Iyengar P, Solomon BJ, et al · · 2021 · cited 9× · PMID 34430379 · DOI 10.21037/tlcr-20-994
7. Defeating lethal cancer: Interrupting the ecologic and evolutionary basis of death from malignancy.
   Pienta KJ, Goodin PL, Amend SR. · · 2025 · cited 8× · PMID 40057846 · DOI 10.3322/caac.70000
8. Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals <i>EGFR</i> Mutations to Be Associated With Longer Overall Survival.
   De B, Farooqi AS, Mitchell KG, Ludmir EB, et al · · 2023 · cited 8× · PMID 36716413 · DOI 10.1200/po.22.00540